JACC Associate Editor Celina M. Yong, MD, FACC, and JACC: Case Reports Editor in Chief Gilbert H. L. Tang, MD, MSc, MBA, FACC, discuss this paper published in JACC and presented at TCT. TRILUMINATE Pivotal is the first randomized, controlled trial evaluating transcatheter edge-to-edge repair (T-TEER) for severe tricuspid regurgitation (TR). Adaptive design randomized 572 subjects in the primary or subsequent cohorts. Subjects were elderly with atrial fibrillation and prior HFH. Primary endpoint ...
Oct 27, 2024•3 min
In the October 29, 2024 issue of JACC, Dr. Valentin Fuster explores groundbreaking studies on heart failure treatments, including the impact of sacubitril-valsartan on hypotension, the benefits of intravenous iron for reducing hospitalizations, the prognostic value of platelet FCγRIIA in post-myocardial infarction patients, and innovative AI assessments of environmental factors influencing cardiovascular risk.
Oct 21, 2024•24 min
In this episode, researchers explore how asymptomatic versus symptomatic hypertension affects heart failure patients on sacubitril valsartan, finding that both types are linked to worse outcomes, but the drug's benefits remain strong, suggesting clinicians should avoid stopping treatment based solely on blood pressure.
Oct 21, 2024•10 min
In this episode, Dr. Zhuo Chen and his team explore how AI-driven analysis of neighborhood satellite imagery can reveal links between the built environment and cardiovascular risk. Their findings suggest that while AI can predict adverse cardiovascular events, the influence of social determinants, particularly socioeconomic status, plays a critical role in this relationship, underscoring the need for further research into these complex interactions.
Oct 21, 2024•13 min
In this episode, Dr. David J. Schneider research identifies platelet FCγRIIA (PFCG) as a key biomarker for cardiovascular risk post-myocardial infarction. In an 800-patient study, higher PFCG levels were linked to increased risks of myocardial infarction, stroke, and death, indicating its potential for guiding personalized antiplatelet therapy, pending further validation.
Oct 21, 2024•10 min
In this episode, Dr. Valentin Fuster reviews the Ironman trial, which studied the effects of intravenous iron on patients with heart failure and iron deficiency. While intravenous iron improved symptoms and reduced recurrent hospitalizations, it did not significantly impact first-time hospitalizations or mortality rates, suggesting the need for further research into its broader clinical benefits.
Oct 21, 2024•11 min
In this episode, Dr. Valentin Foster introduces a vital review on aspirin hypersensitivity in patients with atherosclerotic cardiovascular disease, led by Dr. Mattia Galli and Dr. Dominick J. Angiolillo. The discussion spans the history, epidemiology, and mechanisms of aspirin hypersensitivity, alongside strategies for management and practical recommendations for healthcare providers.
Oct 21, 2024•27 min
In this episode, Dr. Valentin Fuster summarizes the pivotal October 2024 issue of the JACC Journal, focusing on the intersection of obesity and cardiology. Key discussions include the revolutionary impact of anti-obesity medications like semaglutide on heart health, the intricate relationship between obesity and heart failure with preserved ejection fraction, and the urgent need for equitable access to these therapies for improved cardiovascular outcomes.
Oct 14, 2024•22 min
In this episode, Dr. Valentin Fuster discusses a pivotal study on inflammation's role in obesity-related heart failure with preserved ejection fraction, highlighting findings from the STEP heart failure program. The research reveals that semaglutide improves heart failure symptoms and reduces inflammation across varying baseline CRP levels, suggesting cardiovascular benefits that extend beyond weight loss alone.
Oct 14, 2024•10 min
In the October 22, 2024 issue of JACC, a podcast explores the promising benefits of semaglutide, a glucagon-like peptide receptor agonist, in treating obesity-related heart failure. The episode discusses key findings from original research, highlighting how semaglutide improves cardiac structure and function, attenuates adverse remodeling, and showcases the dual mechanisms—both weight-related and independent—behind these effects.
Oct 14, 2024•6 min
In this episode, Dr. Valentin Foster explores the October 2024 issue of JACC, highlighting the significant benefits of semaglutide, particularly for individuals with obesity and cardiovascular disease. He focuses on findings from the SELECT trial, which demonstrate that semaglutide reduces overall and cardiovascular mortality, as well as COVID-19 related deaths, emphasizing the need for continued innovative research in addressing health challenges.
Oct 14, 2024•10 min
In this episode, Dr. Valentin Foster highlights the October 2024 issue of JACC, which delves into the benefits of semaglutide for obesity-related heart failure with preserved ejection fraction. A key study presented shows that semaglutide significantly improves heart failure symptoms and physical limitations, particularly in patients with a history of atrial fibrillation, underscoring its efficacy beyond mere weight loss.
Oct 14, 2024•7 min
In this episode, Dr. Valentin Foster explores the October issue of JACC, which highlights obesity and the potential benefits of glucagon-like peptide receptor agonists, particularly semaglutide, in treating heart failure. He delves into the FLOW trial, revealing how semaglutide significantly reduced heart failure events and cardiovascular death in patients with type 2 diabetes and chronic kidney disease, while also addressing the study's limitations and the need for improved diagnostic criteria ...
Oct 14, 2024•8 min
Dr. Sardari Nia's trial on digital cardiac counseling, presented at EACTS and published in JACC, is a randomized study of 394 patients. It investigated the impact of telemedicine-based prehabilitation to reduce modifiable risk factors in patients awaiting elective cardiac surgery. The results demonstrated a significant 35% reduction in major adverse events, particularly rehospitalizations, highlighting the safety and effectiveness of prehabilitation in improving patient outcomes. This trial also...
Oct 11, 2024•14 min
In this episode, Dr. Valentin Fuster discusses a groundbreaking study linking urinary metal levels, particularly non-essential metals like cadmium and uranium, to coronary artery calcification, highlighting their potential role in cardiovascular disease. The findings underscore the urgent need for public health initiatives to address environmental metal exposure, as they could significantly mitigate cardiovascular risks and health disparities.
Oct 07, 2024•11 min
In this episode, Dr. Valentin Fuster discusses a pivotal study comparing bivalirudin and heparin anticoagulation in STEMI patients undergoing primary PCI, highlighting that bivalirudin may reduce cardiac mortality and bleeding without increasing thrombotic events. While the findings challenge previous guidelines favoring heparin, limitations in the research prompt caution about immediate changes to clinical practice, emphasizing the need for further exploration of bivalirudin's role in diverse p...
Oct 07, 2024•9 min
In this episode, Dr. Valentin Fuster summarizes the October 2024 issue of the JACC Journal, highlighting four pivotal studies on atrial fibrillation, anticoagulation strategies in STEMI, heart failure risk assessment, and the impact of urinary metal levels on coronary artery calcification. Emphasizing the increasing prevalence of atrial fibrillation and the critical role of biomarkers, he underscores the urgent need for enhanced prevention strategies and public health actions regarding environme...
Oct 07, 2024•24 min
In this insightful episode of JACC, Dr. Valentin Fuster summarizes groundbreaking international clinical practice guidelines for acute pulmonary embolism, authored by Dr. Marco Suin and colleagues. The discussion delves into key aspects such as diagnosis, risk stratification, immediate anticoagulation, and advanced therapies, highlighting the challenges and recommendations that can ultimately guide clinicians in managing this critical condition.
Oct 07, 2024•34 min
In the October 15, 2024, issue of JACC, Dr. Valentin Fuster highlights a crucial study revealing that the prevalence of diagnosed atrial fibrillation in the U.S. has surged to at least 10.5 million adults, driven by factors like aging, obesity, and diabetes. With a call for improved prevention and treatment strategies, experts stress the urgent need for public health initiatives to tackle this growing burden on the healthcare system.
Oct 07, 2024•10 min
In the October 15, 2024 issue of JACC, a study led by Dr. Paul Haller investigates the use of biomarkers—NT-proBNP, high-sensitive cardiac troponin T, and GDF-15—to assess heart failure risk in patients with atrial fibrillation. The findings reveal that these biomarkers significantly enhance risk stratification, suggesting their potential to identify patients at varying risks for heart failure and improve clinical management.
Oct 07, 2024•11 min
Michelle M Kittleson, MD, FACC, JACC Associate Editor, speaks with author Muthiah Vaduganathan, MD on his accepted paper concerning the FINEARTS trial published in JACC.
Oct 04, 2024•11 min
Akshay S. Desai, MD, FACC presents his accepted HFSA presentation concerning the FINEARTS trial published in JACC, with commentary by Theresa McDonagh, MBBCH, JACC Associate Editor.
Oct 04, 2024•18 min
In the October 8, 2024 issue of JACC, a pivotal study explores the prognostic implications of various diagnostic criteria for myocarditis, comparing the European Society of Cardiology and the late-luis criteria. The findings reveal that while most patients can be diagnosed using ESC criteria, the combination of both sets enhances risk stratification, emphasizing the need for collaboration between clinical cardiologists and imaging specialists in managing suspected myocarditis cases.
Sep 30, 2024•13 min
In the October 8, 2024, issue of JACC, Dr. Casper Bonison and colleagues present a study on the risks of ischemic stroke recurrence after PFO closure, revealing that while the four-year risk remains higher than the general population, it mirrors clinical trial findings. They emphasize the importance of careful patient selection and the need for further research into closure techniques and associated stroke risk factors.
Sep 30, 2024•9 min
In this episode, Dr. Valentin Fuster introduces a crucial consensus document on Critical Care Cardiology training, highlighting insights from leading experts at the University of Minnesota and Harvard. With the field rapidly expanding and 20% of incoming cardiology fellows expressing interest in this specialty, the panel outlines key recommendations for enhancing training programs to meet evolving demands.
Sep 30, 2024•4 min
In this episode, Dr. Valentin Fuster discusses a groundbreaking study that evaluates the role of myocardial fibrosis in predicting sudden cardiac death and ventricular arrhythmias in patients with non-ischemic cardiomyopathy. The findings suggest that assessing fibrosis through advanced imaging techniques offers a more accurate risk stratification than the traditional reliance on left ventricular ejection fraction, ultimately refining treatment approaches for at-risk patients.
Sep 30, 2024•12 min
In this episode, Dr. Valentin Fuster highlights groundbreaking research from the October 8, 2024 issue of JACC. Key studies delve into the evolving diagnostic criteria for myocarditis, the prognostic value of subclinical atherosclerosis, the arrhythmic risks in non-ischemic cardiomyopathy, and the implications of PFO closure on ischemic stroke risk, underscoring the importance of advanced imaging techniques and clinical criteria in modern cardiovascular care.
Sep 30, 2024•30 min
In this episode, experts discuss a crucial 2024 document outlining appropriate use criteria for multimodality imaging in cardiovascular evaluation before non-emergent non-cardiac surgery, addressing the rising annual surgeries and associated cardiac risks. They delve into balancing the necessity of imaging with cost-effectiveness while exploring the potential of artificial intelligence to enhance future evaluations.
Sep 30, 2024•9 min
In this episode, Dr. Valentin Fuster discusses groundbreaking research on the impact of subclinical atherosclerosis on mortality, revealing insights from a 15-year study. He emphasizes the limitations of traditional cardiovascular risk prediction tools, like the Framingham Risk Score, and calls for deeper exploration of individual risk factors for better long-term outcomes.
Sep 30, 2024•12 min
Michelle M Kittleson, MD, FACC, JACC Associate Editor, speaks with author Muthiah Vaduganathan, MD on his accepted paper concerning the FINEARTS trial published in JACC.
Sep 28, 2024•7 min
